AMSTERDAM and BOSTON, May 31,
2018 /PRNewswire/ -- Royal
Philips (NYSE: PHG, AEX: PHIA), a global leader in
health technology, today announced it will be implementing Clinical
Pathways from the Dana-Farber Cancer Institute, a leading center of
cancer research and treatment, and founding member of the
NCI-designated Dana-Farber/Harvard Cancer Center, to establish best
practices in cancer care. The Dana-Farber Clinical Pathways will be
deployed through the Philips IntelliSpace Oncology Platform,
providing clinical decision support to physicians via a
patient-centric solution. The implementation will help oncologists
quickly reach the most appropriate cancer treatments for patients,
based on the unified view of the patient across diagnostic
modalities and the embedded knowledge of Clinical Pathways, and can
be delivered through existing EHR platforms.
Cancer is an incredibly complex set of diseases and the amount
of information and treatment options available can be challenging
to cope with for oncologists. Philips will leverage Dana-Farber
Clinical Pathways to effectively map cancer patients to the
appropriate treatment options. Philips will power this clinical
decision support through its oncology informatics suite, which
integrates radiology, pathology, genomics and EHR data to support
pathways to scale precision medicine.
For example, in patients whose chronic myelogenous leukemia is
progressing after first-line therapy, Dana-Farber Pathways helps
physicians sort through over a dozen different possible resistance
mutations and a handful of targeted therapies with very different
side effect profiles to find the most appropriate treatment for
that particular patient.
"Every cancer patient deserves the best possible care. Our
Clinical Pathways provide physicians with the most current,
evidence-based best practices so that all patients may be treated
with the same high standard of care," said Dr. Laurie H. Glimcher, CEO, Dana-Farber. "Cancer
medicine is changing rapidly, and physicians are tasked with
interpreting massive amounts of new information generated from
publications and clinical trials. Through this collaboration
with Philips, we can help them choose the best possible treatment
for patients based on specific information and the deep experience
of our clinicians."
"Patient-centric care is key to providing the best cancer
treatment to those who need it," said Frans
van Houten, CEO of Royal
Philips. "Together with our partners, we aim to optimize the
flow of patient information from various sources and streamline
care delivery through the adoption of best practices. By leveraging
the unrivaled clinical knowledge and expertise incorporated in
Dana-Farber Clinical Pathways, Philips' oncology informatics suite
of technologies can assist in providing the most effective care for
people based on their genome, and then put it in the hand of
doctors through clinical decision support."
Dana-Farber Clinical Pathways will provide best practices from
the institute's leading oncologists and extensive care teams to
support cancer treatment, leveraging the integrated diagnostic
capabilities of Philips IntelliSpace Oncology, a cloud-based
precision medicine platform that integrates information across
different clinical domains. As cancer treatment changes regularly,
updates will be made to each pathway several times a year.
For more information on Philips collaboration with Dana-Farber,
the full portfolio of Philips oncology informatics solutions and
Philips' presence at the American Society of Clinical Oncology
(ASCO) Annual Meeting, visit Booth #7159 on the exhibit floor, and
follow @PhilipsLiveFrom for #ASCO18 updates throughout the
event.
For further information, please contact:
Kathy O'Reilly
Philips Group Press Office
Tel: +1 978-221-8919
E-mail: Kathy.Oreilly@Philips.com
Twitter: @kathyoreilly
Ellen Berlin
Director of Media Relations, Dana-Farber Cancer Institute
Tel : 617-632-4090
E-mail : ellen_berlin@dfci.harvard.edu
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2017 sales of
EUR 17.8 billion and employs
approximately 74,000 employees with sales and services in more than
100 countries. News about Philips can be found
at www.philips.com/newscenter.
About Dana-Farber Cancer Institute
From
achieving the first remissions in childhood cancer with
chemotherapy in 1948, to developing the very latest new therapies,
Dana-Farber Cancer Institute is one of the world's leading centers
of cancer research and treatment. It is the only center ranked
in the top 4 of U.S. News and World Report's Best Hospitals for
both adult and pediatric cancer care.
Dana-Farber sits at the center of a wide range of collaborative
efforts to reduce the burden of cancer through scientific inquiry,
clinical care, education, community engagement, and
advocacy. Dana-Farber/Brigham and Women's Cancer
Center provides the latest in cancer care for
adults; Dana-Farber/Boston Children's Cancer and Blood
Disorders Center for children. The Dana-Farber/Harvard Cancer
Center unites the cancer research efforts of
five Harvard academic medical centers and two graduate
schools, while Dana-Farber Community Cancer Care provides
high quality cancer treatment in communities
outside Boston's Longwood Medical Area.
Dana-Farber is dedicated to a unique, 50/50 balance between
cancer research and care, and much of the Institute's work is
dedicated to translating the results of its discovery into new
treatments for patients locally and around the
world.
View original content with
multimedia:http://www.prnewswire.com/news-releases/philips-and-dana-farber-operationalize-and-scale-clinical-pathways-at-asco-2018-300657048.html
SOURCE Royal Philips